dupilumab
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Moderate-to-Severe Atopic Dermatitis
Conditions
Moderate-to-Severe Atopic Dermatitis, Atopic Eczema
Trial Timeline
Jan 11, 2023 → Nov 14, 2024
NCT ID
NCT05590585About dupilumab
dupilumab is a approved stage product being developed by Sanofi for Moderate-to-Severe Atopic Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05590585. Target conditions include Moderate-to-Severe Atopic Dermatitis, Atopic Eczema.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05906706 | Pre-clinical | Completed |
| NCT07316114 | Pre-clinical | Recruiting |
| NCT07467564 | Pre-clinical | Recruiting |
| NCT07187089 | Approved | Withdrawn |
| NCT07112378 | Phase 3 | Recruiting |
| NCT07052396 | Pre-clinical | Recruiting |
| NCT07276425 | Pre-clinical | Recruiting |
| NCT06695897 | Pre-clinical | Recruiting |
| NCT06693531 | Pre-clinical | Recruiting |
| NCT06415175 | Pre-clinical | Active |
| NCT06556264 | Approved | Recruiting |
| NCT06352073 | Approved | Recruiting |
| NCT06293053 | Phase 3 | Recruiting |
| NCT05983068 | Approved | Active |
| NCT06234761 | Pre-clinical | Recruiting |
| NCT05991323 | Pre-clinical | Active |
| NCT06192563 | Pre-clinical | Recruiting |
| NCT06169527 | Pre-clinical | Active |
| NCT06393946 | Pre-clinical | Active |
| NCT05831176 | Phase 2 | Active |
Competing Products
13 competing products in Moderate-to-Severe Atopic Dermatitis